Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (3072)	8/24/2016 6:37:21 PM
From: tuck	Respond to of 3158

RE: LXRX >>dual GLP1&2 inhibitor<< mistyped. meant dual SLGT1&2 inhibitor

To: tuck who wrote (3072)	8/24/2016 8:34:23 PM
From: Miljenko Zuanic	Respond to of 3158

My view: OPHT is a hype because Fovista (so far) do not bring sufficient benefit to warrant additional hassle and cost. IF P3 are positive, durable ...4-6 letters, and no significant increase in adverse events that maybe we can talk about market value. PBYI..."shit" hype, nothing more. LXRX (have position) has that dual inhibitor and IF there is deference from single ones (currently doing nicely in diabetes market) than we should expect further appreciation in MC. RARE is potential munch, but how to allocate appropriate MC value is out of my reach. INCY and BMRN....will they accept/adapt munch option??? SGEN is hard to valuate properly..too many unknowns.